Jasmina Brooks News Today

All 20 participants in a 12-month follow-up study attained acute success from ablation procedures.

Johnson & Johnson MedTech's Biosense Webster announced today that it submitted its Varipulse platform to the FDA for premarket approval.

/PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, today announced European CE mark...

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, today announced European CE mark approval of the VARIPULSE™ Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF) using pulsed field ablation (PFA). The VARIPULSE™ Platform is comprised...

J&J MedTech's Biosense Webster unit announced today that it won CE mark approval for its Varipulse pulsed field ablation platform.

Biosense Webster today announced its support for two collaborative studies using its Varipulse pulsed field ablation platform.

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation 

Johnson & Johnson MedTech's Biosense Webster announced positive findings from real-world data looking at its AFib ablation technology.

J&J announces that Biosense Webster, a global specialist in the treatment of cardiac arrhythmia and part of Johnson & Johnson MedTech, has received approval from Japans Ministry of Health, Labor and...

Johnson & Johnson MedTech's Biosense Webster today announced Japanese approval for its Varipulse platform for treating AFib.